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Poor outcomes with cryoplasty for lower extremity
arterial occlusive disease
Gregory C. Schmieder, MD, Megan Carroll, BA, BS, and Jean M. Panneton, MD, Norfolk, Va
Objectives: Cryoplasty has been proposed as a different therapy to address the problems of recurrent lesions. We
reviewed our experience with cryoplasty to determine its outcome treating patients with lesions in native vessels and
within stents.
Methods: A retrospective review of all patients undergoing cryotherapy between 2004 and 2008 was conducted. Patency
was defined by at least one of the following criteria: flow through the vessel demonstrated by angiography or duplex
ultrasonography, maintenance of an ankle-brachial index (ABI) greater than 0.10 above the preprocedural value, or
maintenance of a palpable pedal pulse that was absent before the procedure in an asymptomatic patient. Patency,
limb salvage, symptomatic improvement, and freedom from surgical bypass were determined with Kaplan-Meier
survival analysis and compared by log-rank testing. Multivariate analysis was performed by Cox proportional-
hazards regression.
Results: Eighty-eight cryoplasty procedures were performed in 71 patients, with 35 procedures for in-stent restenosis and
37 for native vessel disease. Sixteen of 88 procedures in grafts were excluded from analysis secondary to combined disease
process and/or bypass graft stenosis. Lesions treated with cryoplasty had an average of 2.9 prior endovascular
interventions. Eighty-five percent of the lesions were described as complex (multifocal, diffuse, or occlusion) and the
mean lesion length was 15 10 cm. Initial cryoplasty technical success rate was 68% (25 of 37) for native vessels and 71%
(25 of 35) for in-stent procedures. One year primary patency for the native vs stent group was 17% vs 28%, respectively
(P  .18). The 1-year primary assisted patency for the native vs stent group was 28% vs 47%, respectively (P  .33). The
1-year secondary patency for the native vs stent group was 41% vs 57% (P .42), respectively. Freedom from claudication
at 1 year for the native vs stent group was 32% vs 21% (P  .80). Compared to balloon angioplasty, cryoplasty has an
averaged up-cost of $1851.50 per procedure.
Conclusion: Cryoplasty was used in patients with extensive disease and multiple prior interventions. Cryoplasty
provided poor patency rates and poor relief from claudication at 1 year in this population. Overall, cryoplasty seems
to be an expensive endovascular tool with marginal clinical improvement in our experience. ( J Vasc Surg 2010;52:
362-8.)Endovascular therapy for infrainguinal arterial occlu-
sive disease has rapidly expanded over the last decade.
Lower patency rates compared to open revascularization
have continued to plague endovascular therapies. Resteno-
sis occurs in 30% to 80% of patients treated with percuta-
neous transluminal angioplasty,1 and in 40% of patients
within 1 year of stent placement.2 Due to recurrent steno-
sis, reintervention is often necessary. Cryoplasty (PolarCath
Peripheral Dilatation System; Boston Scientific Corp,
Natick, Mass) has been introduced as a procedure that will
reduce restenosis in vessels and improve the long-term
patency of the revascularization procedure. Cryoplasty was
From the Division of Vascular Surgery, Eastern Virginia Medical School,
Norfolk, Va.
Competition of interest: none.
Megan Carroll is the recipient of the American Vascular Association Lifeline
Student Research Fellowship.
Presented at the Thirty-seventh Annual Meeting of the Society for Clinical
Vascular Surgery in Fort Lauderdale, Fla, March 17-20, 2009.
Reprint requests: Jean Panneton, MD, Eastern Virginia Medical School,
Division of Vascular Surgery, Sentara Heart Hospital, 600 Gresham
Drive, Suite 8620, Norfolk, VA 23507 (e-mail: pannetjm@evms.edu).
The editors and reviewers of this article have no relevant financial relation-
ships to disclose per the JVS policy that requires reviewers to decline
review of any manuscript for which they may have a competition of
interest.
0741-5214/$36.00
Copyright © 2010 by the Society for Vascular Surgery.
doi:10.1016/j.jvs.2010.03.012
362approved by the Food&Drug Administration in August of
2003 for dilation of stenosis in the peripheral vasculature of
the iliac, femoral, popliteal, infrapopliteal, and renal arter-
ies. The theory behind cryoplasty’s use is that the liquid
nitrous oxide which is used to inflate the procedural bal-
loon causes the surrounding vessel to freeze at -10°C, and
then the vessel is slowly rewarmed causing apoptosis to be
induced at the site of intervention.3 The induction of
apoptosis by cryoplasty is thought to reduce the inflamma-
tory response which results in a decreased likelihood of
restenosis.4 Initial research on the efficacy of cryoplasty has
shown that cryoplasty is able “to restore normal arterial
flow with sustained patency.”5 A large, multicenter study
by Laird et al6 shows clinical patency rates for cryoplasty to
be 82.3% after 300 days and maintained at 75% after 3
years. Furthermore, Das et al7 have shown cryoplasty to be
“a safe and effective method of treating infrapopliteal dis-
ease, providing excellent acute outcomes and a high rate of
limb salvage in patients with critical limb ischemia” with an
amputation-survival rate of 89.3% at 180 days. While cryo-
plasty has been shown to decrease the rate of restenosis and
increase vessel patency in these studies, the researchers did
not differentiate between patients with in-stent restenosis
and those with native lesions. Whether or not the data
presented in these studies reflects the ability of cryoplasty to
treat patients with in-stent restenosis remains unclear. We
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define the technical feasibility, patency, and clinical out-
comes of cryoplasty.
MATERIALS AND METHODS
A retrospective review was performed on patients in
whom cryoplasty therapy was used to treat lower extremity
arterial occlusive disease fromMarch 1, 2004 throughMay
31, 2008. Codes on hospital charge sheets were used to
identify those patients who underwent cryoplasty. Patient
demographics, clinic notes, noninvasive vascular studies,
angiographic findings, and operative reports were reviewed
after approval by the Institutional Review Board.
During this period, 88 limbs with arterial occlusive
disease were treated with cryoplasty in 71 consecutive
patients. The use of cryoplasty was left to the discretion of
the surgeon. The treated segments ranged from the com-
mon iliac artery to the tibial arteries. Characteristics of the
treated lesions were described by lesion type (stenosis vs
occlusion), stenotic lesions were further divided by distri-
bution (isolated focal [isolated lesions 5 cm], multifocal
[noncontiguous isolated lesions, which individually are5
cm], and diffuse [contiguous lesions 5 cm]), presence of
calcification, and lesion length (sum total length of treated
segments, contiguous, and noncontiguous). Vessel types
were defined as native artery (no prior stents or devices
implanted), in-stent (treated segment within 1 cm proximal
and distal of stent), graft (previous bypass grafts within the
conduit and within 1 cm of proximal and distal anastomo-
sis), or a combination of any of the preceding vessel types.
Previous interventions were defined as endovascular inter-
ventions performed prior to the intervention in which
cryoplasty was used. Prior bypass surgeries were defined as
any open surgical bypass performed on the limb undergo-
ing an intervention. Primary procedure was defined as the
first intervention undertaken in the procedural course in
which cryoplasty was used. Secondary, tertiary, or quater-
nary procedures were those interventions that followed the
primary procedure during the same treatment. Reinterven-
tions were defined as procedures performed at a completely
separate treatment time.
All procedures were performed in an angiographic suite
with the patient under local anesthesia and moderate seda-
tion. The common femoral artery contralateral to the
treated limb was the preferred means of angiographic ac-
cess. After angiography and identification of an arterial
lesion, patients were systemically heparinized; no IIb/IIIa
inhibitors were used. The lesions were typically approached
by placement of a longer sheath over the aortic bifurcation
and in proximity to the lesion. Treatment was deemed
technically successful if a residual stenosis of less than 30%
was obtained. Initial cryoplasty technical success defines
those procedures in which cryoplasty produced a residual
stenosis less than 30% and after which no other therapies
were used. Overall procedural success is determined by the
outcome after the whole procedural course, ie, after pri-
mary and all adjunctive procedures. Stents were selectively
deployed within segments of the channel for suboptimalangioplasty, defined as residual stenosis greater than 30% or
flow-limiting lesions. After the procedure, patients received
75 mg clopidogrel for at least 1 month and aspirin indefi-
nitely. Patients were allowed to resume ambulation 6 to 8
hours after the procedure and were typically discharged
home the same day or within 24 hours.
Clinical follow-up at 1 month, 3 months, and 6 to 12
months after the procedure was routine and included phys-
ical examination and measurement of ankle-brachial indi-
ces. Duplex examination of the treated artery and further
follow-up were obtained at the discretion of the treating
surgeon. Any additional endovascular procedures to main-
tain or restore patency were recorded, as were all open
surgical revisions, bypasses, and major amputations per-
formed through December 31, 2008.
Patency was defined by at least one of the following
criteria: flow through the vessel demonstrated by angiog-
raphy or duplex ultrasonography (50% stenosis defined
by doubling of peak systolic velocity), maintenance of an
ankle-brachial index (ABI) greater than 0.10 above the
preprocedural value, or maintenance of a palpable pedal
pulse that was absent before the procedure in an asymp-
tomatic patient. Resolution of symptoms, per se, was not
considered a confirmation of patency. Any follow-up inter-
vention necessitating open surgical revision or bypass was
reported as such and was not included in primary assisted or
secondary patency. Symptomatic improvement in patients
with claudication was defined as improvement in walking
distance, as determined through follow-up visits; this was a
qualitative measurement, not quantitative.
Continuous data are expressed as mean SD and were
compared by using the t-test. Noncontinuous data are
expressed as percentages and were compared by using the
z-test comparison for proportions. A P value  .05 was
considered statistically significant. Patency, limb salvage,
symptomatic improvement, and freedom from surgical by-
pass were determined with Kaplan-Meier survival analysis
and compared by log-rank testing.Multivariate analysis was
performed by Cox proportional hazards regression. Pa-
tency is presented in terms of technical success.
RESULTS
Descriptive analysis. Seventy-one patients (88 limbs)
underwent cryoplasty for CLI, disabling claudication, or
asymptomatic restenosis fromMarch 1, 2004 throughMay
31, 2008. Cryoplasty was performed on 37 (42%) native
arteries, 35 (40%) stented arteries, 6 (7%) bypass grafts, and
10 (11%) combination vessel types (9 native and stented
arteries; 1 bypass graft and stent). The bypass graft and
combination vessel types were excluded from analysis be-
cause these cohorts were too small to analyze on their own
and too different to be included in one of the groups.
Further analysis will focus on the native artery (native) and
stented artery (stent) groups only. The mean follow-up was
14.6 months (range, 0-57 months); there was no statistical
difference in follow-up duration between the two groups.
Patient demographics are presented in Table I. Patients in
the native group had a mean age of 67 10, while those in
teristi
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majority of patients in each group were white men. Overall,
there were no differences in risk factors for atherosclerosis
between the two groups, except a slight trend for a higher
prevalence of end-stage renal disease (ESRD) in the native
group (24% native vs 10% stent; P .12). The stent group
had a higher rate of previous surgical bypass procedures
compared to the native group (29% stent vs 9% native;
P  .045).
The majority of interventions were performed for life-
style limiting claudication (native 62% vs stent 69%; P 
.57). Other indications for cryoplasty were CLI (native 24%
vs stent 14%; P .15) and asymptomatic restenosis (native
14% and stent 17%; P  NS). All the patients who were
“asymptomatic” presented for reintervention. The first in-
tervention was performed for CLI in 6 patients and claudi-
cation in the other 5 patients. The stent group had under-
gone more previous interventions prior to cryoplasty than
the native group (100% vs 46%; P  .001). Of those
patients who had undergone previous intervention, the
mean number of previous endovascular interventions per
patient were similar between both groups (native 2.8 vs
stent 3.1; P  .64).
The lesions were equally distributed throughout the
lower extremity between each group (Table II). The ma-
jority of lesions were located in the superficial femoral
Table I. Patient demographics and risk factors for periphe
Variable
Total*
(limbs-88; 71 pts)
Age (y)
Mean  SD 65  11
Range 33-91
Male gender 58% (41)
White 65% (46)
African American 35% (25)
Indication
Asymptomatic 18% (16)
Critical limb ischemia 20% (17)
Rest pain 6% (5)
Ulceration 8% (7)
Gangrene 6% (5)
Claudication 63% (55)
Risk factors
Hypertension 84% (59)
Diabetes mellitus 54% (38)
Coronary artery disease 74% (52)
History of smoking 80% (56)
End-stage renal disease 17% (12)
Dyslipidemia 77% (54)
Congestive heart failure 11% (8)
Previous LE bypass 26% (18)
Nonoperative candidate 39% (32)
Previous endovascular
interventions
77% (68)
Mean number 2.9  2.7
Range 1-12
LE, Lower extremity; Pts, patients.
*Patient demographics calculated by number of patients; procedural characartery only (native 51% vs stent 51%; P  NS). The nativegroup also had three combination lesions that spanned the
superficial femoral-popliteal-infrapopliteal arteries. The
stent group had four combination lesions that were distrib-
uted across the iliac-common femoral artery (1), iliac-
superficial femoral artery (1), superficial femoral-infrapopliteal
artery (1), and popliteal-infrapopliteal artery (1). Lesion
lengths ranged from 3 to 36 cm. The mean lesion length
was similar between the native and stent group (native 14.5
cm 9 vs stent 13.3 cm 9.5; P .61). There was better
vessel runoff in the stent group compared to the native
group (2.3 0.8 vs 1.8 0.8; P .05). The native artery
group lesions were 73% stenosis and 27% occlusions com-
pared to 57% stenosis and 43% occlusions in the stent group
(P  .16). In addition, for both groups the majority of
stenotic lesions were described as complex, ie, multifocal or
diffuse.
In the native artery group, cryoplasty was used as the
primary intervention in 73% (n  27 of 37) and as adjunc-
tive intervention in 27% (n  10 of 37). The interventions
performed immediately prior to cryoplasty included in-
traluminal angioplasty (n 6), subintimal angioplasty (n
3), and laser atherectomy (n  1). In 1 patient, cryoplasty
was used as the tertiary procedure after subintimal angio-
plasty and repeat angioplasty. Initial cryoplasty technical
success was achieved in 68% (n  25) of limbs. Of the 12
initial cryoplasty failures, 5 patients were treated with ad-
rterial disease
ative artery*
mbs-37; 33 pts)
Stent*
(limbs-35; 31 pts) P value
67  10 65  11 .43
50-91 45-89 —
58% (19) 61% (19) .76
64% (21) 71% (22) .53
36% (12) 29% (9) .53
14% (5) 17% (6) .84
24% (9) 14% (5) .15
3% (1) 9% (3) .28
11% (4) 3% (1) .19
11% (4) 3% (1) .19
62% (23) 69% (24) .57
76% (25) 90% (28) .12
52% (17) 55% (17) .79
76% (25) 74% (23) .89
73% (24) 84% (26) .28
24% (8) 10% (3) .12
67% (22) 84% (26) .11
6% (2) 13% (4) .35
9% (3) 29% (9) .045
33% (11) 35% (11) .84
46% (17) 100% (35) .001
2.8  2.7 3.1  2.0
1-10 1-12
cs calculated by number of limbs.ral a
N
(lijunctive balloon angioplasty to attain technical success.
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patients. Ten limbs underwent stent placement in the na-
tive group. Six stents were placed for flow-limiting dissec-
tion and four were placed for a suboptimal result. Despite
stent placement, seven limbs still did not attain technical
success. These seven technical failures were secondary to
dissections and two were due to suboptimal results.
In the stent group, cryoplasty was used as the primary
intervention in 66% (n  23 of 35) and as adjunctive
intervention in 34% (n  12 of 35). The interventions
performed immediately prior to cryoplasty included in-
traluminal angioplasty (n  10), mechanical atherectomy
(n  1), and mechanical thrombolysis with tissue plasmin-
ogen activator (n  1). Cryoplasty was used as the tertiary
procedure in 3 patients. The procedural course prior to
cryoplasty in these patients was angioplasty and subsequent
repeat angioplasty, angioplasty and subsequent mechanical
atherectomy, and laser atherectomy and subsequent angio-
plasty. Eight patients who presented with an occlusion
underwent cryoplasty as their first intervention. In 6 of
these patients, the wire passed easily, whereas the 2 other
patients required a sequential injection analysis technique.
Initial cryoplasty technical success was achieved in 71% (n
25) of limbs. Six initial cryoplasty failures were treated with
adjunctive balloon angioplasty to attain technical success.
Overall procedural success was achieved in 89% (n 31) of
cases. All four technical failures were secondary to a subop-
timal result. Three limbs underwent repeat stent placement
in the stent group for a suboptimal result. Despite stent
Table II. Characteristics of cryoplasty-treated lesions treat
Variable Total (88)
Location of lesion
Iliac only 3% (3)
SFA only 51% (45)
SFA-popliteal 15% (13)
Popliteal only 14% (12)
Infrapopliteal 2% (2)
Combination 15% (13)
Lesion type
Native artery only 42% (37)
Stent only 40% (35)
Graft only 16% (6)
Combination 12% (10)
Native and stent 10% (9)
Graft and stent 2% (1)
Lesion characteristics
Stenosis 62% (55)
Isolated focal 15% (13)
Multifocal 20% (18)
Diffuse 27% (24)
Occlusion 38% (33)
Lesion calcification 8% (7)
Lesion length
Mean 15 cm  10 cm
Range 2-46 cm
Vessel runoff 2  1
Range (1-3)
SFA, Superficial femoral artery.placement, two limbs still did not attain technical success.There were no statistically significant differences between
the native and stent group for either initial cryoplasty
technical success or overall procedural success rates.
Outcome analysis. The native group had 30 techni-
cally successful interventions; however, 4 patients were lost
to follow-up. Therefore, analysis was performed on the 26
remaining patients. The stent group had 31 technically
successful interventions without any patients lost to follow-
up. One-year primary patency for the native vs stent group
was 17% vs 28%, respectively (P  .18; Fig 1). The 1-year
primary assisted patency for the native vs stent group was
28% vs 47%, respectively (P  .33; Fig 2). The 1-year
secondary patency for the native vs stent group was 41% vs
57% (P  .42), respectively (Fig 3). Univariate analysis
within the native group revealed that previous endovascular
intervention adversely affected patency (hazard ratio [HR],
-2.40; P  .05), whereas hypertension (HR, 4.0; P  .01)
and coronary artery disease (HR, 4.55; P  .01) aided
patency. Multivariate analysis, however, only revealed a
trend for previous endovascular intervention adversely af-
fecting patency (Exp [b]- 2.42; P  .12). Univariate anal-
ysis within the stent group revealed that female gender
(HR, -2.56; P  .05) and ESRD (HR, -5.67; P  .01)
adversely affected patency. Univariate analysis of lesion
location, lesion length, or disease type (de novo vs recur-
rent) did not affect patency in both groups. Multivariate
analysis confirmed both variables as significant factors af-
fecting patency (female gender [Exp {b}-2.58; P  .05]
ative (37) Stent (35) P value
3% (1) 6% (2) .52
51% (19) 55% (19) .80
24% (9) 11% (4) .16
11% (4) 17% (6) .44
3% (1) 0% (0) .33
8% (3) 11% (4) .64
00% (37) —
— 100% (35)
— —
— —
— —
— —
73% (27) 57% (20) .16
8% (3) 14% (5) .40
24% (9) 20% (7) .66
41% (15) 23% (8) .11
27% (10) 43% (15) .16
11% (4) 3% (1) .19
cm  9 cm 13.3 cm  9.5 cm .61
3-32 cm 2-36 cm
1.8  0.8 2.3  0.8 .05
(1-3) (1-3)ed
N
1
14.5and ESRD [Exp {b}-6.78; P  .01]).
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the stent group was 32% vs 21% (P  .80). Freedom from
bypass surgery at 1 and 2 years for the native vs the stent
group was 74% and 62% vs 80% and 71%, respectively (P
.63). Six patients in the native group underwent major
amputation at a mean of 9.4 months  5.5 (3.4-18
months). Four of these 6 patients had CLI, whereas 1
patient was a claudicant. One patient with claudication had
an amputation at 1 year after stopping warfarin despite
protein S deficiency. Four patients in the stent group un-
derwent major amputation at a mean 17.9 months  15
Fig 1. Primary patency of the native vs stent groups at 1-year were
17% vs 28% (P  .18), respectively.
Fig 2. Primary assisted patency of the native vs stent groups at 1
year were 28% vs 47% (P  .33), respectively.(1.5-31months). Two of these 4 patients had CLI, whereas2 patients were claudicants. One patient with severely cal-
cified vessels, ESRD, and poor vessel runoff on her third
intervention had an amputation 1½ months postproce-
dure. The second patient with claudication progressed to
amputation 2½ years after cryoplasty, which was the fifth
intervention for that leg. There were no periprocedural
(30 days) deaths in either group. Nine patients died in the
native group during follow-up; mean 19 months  14
(1.9-38 months). There was only one death in the stent
group at 54 months after cryoplasty. The overall survival
was 98% and 96% at 1 and 2 years, respectively.
Five patients (14%) in the native group and 7 patients
(20%) in the stent group encountered procedural compli-
cations. The five complications in the native group were
arterial nonflow-limiting dissections (2), arterial microper-
foration (1), access pseudoaneurysm (1), and distal embo-
lization (1). Only the patient with distal embolus required
conversion to an open procedure. The seven complications
in the stent group were access pseudoaneurysms (3), access
hematoma (1), postoperative myocardial infarction (1),
nonflow-limiting dissection (1), and distal embolization
(1). Again, only the patient with distal embolus required
surgery.
DISCUSSION
The restenosis and occlusion rates after endovascular
therapy for lower extremity arterial occlusive disease have
limited its long-term durability.1,2 Several therapies have
been used to attempt to improve patency over balloon
angioplasty such as stents, drug-eluting stents, atherec-
tomy, and cryoplasty. Cryoplasty works by freezing the
surrounding vessel to 10°C and then allowing the vessel
to slowly rewarm. This action causes apoptosis of the
smooth muscle cells, alteration in the plaque response to
dilation, and reduction of elastic recoil of the vessel wall.
In this study, we share our experience with cryoplasty
Fig 3. Secondary patency of the native vs stent groups at 1 year
were 41% vs 57% (P  .42), respectively.applied to very difficult lesions. Thirty-seven native artery
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cryoplasty. We achieved an initial cryoplasty technical suc-
cess in 68% for the native group and 71% for the stent
group. Most studies on cryoplasty reported technical suc-
cess rates for cryoplasty of 85% to 97%.3,6-10 Our technical
success rate with cryoplasty was decreased for several rea-
sons. First, definitions on technical success have varied
between studies. Das et al7 defined technical success if there
was 50% stenosis after intervention, whereas we used a
30% residual stenosis. Second, we treated very complex
lesions in this study compared to most previous studies,
which treated mainly Trans Atlantic Inter-Societal Consen-
sus (TASC) A and B lesions.3,6-9 This is emphasized by the
mean length of our lesions being 15 cm. Bakken et al10 also
have shown poor initial technical success of 78% with
cryoplasty in more challenging lesions. This is consistent
with our outcomes. Third, the majority of lesions treated
with cryoplasty in our study were reinterventions compared
to previous studies in which all were de novo lesions.3-7
Interestingly, some of our initial cryoplasty failures re-
sponded to balloon angioplasty. This may indicate that
some lesions require a higher inflation pressure, which
cannot be delivered via cryoplasty.
Our 1-year primary patency for cryoplasty for the native
and the stent groups was poor at 17% vs 28%, respectively.
These results are far inferior to previously reported patency
of 57% to 83% for several reasons.3,6-10 First, patency
definitions have varied significantly between studies. Some
have used clinical patency, while others have used target
lesion revascularization. Samson et al8,9 published two
articles on cryoplasty with different definitions of patency.
The first publication using target lesion revascularization
criteria reported a 1-year patency of 82%,8 whereas the
second report using more traditional definitions found a
significant decrease in 1-year patency to 57%.9 Second, as
previously mentioned, this study used cryoplasty for rein-
tervention in 75% of limbs, whereas most studies used
cryoplasty for initial treatment. Only Karthick et al11 eval-
uated cryoplasty use for reintervention in 10 patients. They
reported a 50% and 0% patency at 6 months and 1 year,
respectively. Our study showed a trend for worse patency
for reinterventions compared to initial therapy.
Third, the lesions in our study were more complex than
treated lesions in previous publications. Lesion length in
this study averaged 14 cm, whereas in other studies, the
lesions ranged from 4 to 8 cm.3,6-10 Surowiec et al12 have
shown that as lesion length and complexity increases, out-
comes of endovascular therapy worsen. Bakken et al10
reported a primary patency of 69% for cryoplasty use in
TASC C and D lesions. They, however, did not report the
percentage of lesions in each category, the average lesion
length, and used the older TASC classification. Therefore,
comparison between the Bakken study and our study still
remains difficult. Why would previous interventions, inde-
pendent of the presence of a stent, alter outcomes? The
theory behind cryoplasty is to prevent vessel recoil and
neointimal hyperplasia. Patients who have undergone pre-
vious interventions, however, have already initiated theprocess of vessel recoil and neointimal hyperplasia. There-
fore, any reintervention with cryoplasty may be too late and
unable to fully implement its theoretical benefits.
Multivariate analysis of the native group found a trend
for worse outcomes in patients with prior endovascular
intervention. In multivariate analysis of the stent group, it
seems that female gender and ESRD adversely affect pa-
tency. Black et al13 found renal insufficiency to adversely
affect patency after angioplasty.
There are several limitations of our study. First, its
retrospective design contributed to incomplete data collec-
tion for some preprocedural and postprocedural variables.
This could result in underestimation of patency based on
clinical follow-up. Second, the use of cryoplasty was deter-
mined solely by the surgeon without any specific protocol.
This varied use produced a heterogeneous group of treated
lesions and patients. This study, however, properly reflects
clinical practice. Third, the small numbers in each cohort
make subset analysis difficult to interpret. Finally, patency
could be overestimated by two of three measures used.
There were, however, only a couple of patients whose
patency was determined by examination and approximately
50% were determined by arterial duplex. In addition, loss of
ABI or pulse could actually occur secondary to vascular
disease outside the lesion treated. Therefore, overestima-
tion is less likely.
Despite these limitations, our study does show that
cryoplasty use in difficult lesions and for reintervention will
result in poor patency and clinical outcomes. The role of
cryoplasty in endovascular therapy must be weighed against
its increased cost over balloon angioplasty ($1800). There-
fore, cryoplasty use in these difficult or recurrent lesions
appears to offer minimal benefit.
CONCLUSIONS
Cryoplasty was used in patients with extensive athero-
sclerotic disease and multiple prior interventions. Cryo-
plasty provided poor patency rates and poor relief from
claudication at 1 year in this population. In patients treated
for in-stent restenosis with cryoplasty, patients with ESRD
and female gender will likely have worse outcomes. Overall,
cryoplasty appears to be an expensive endovascular tool
with marginal clinical improvement in our experience.
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